Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 307-313

  Koh, Kwang Kon ^a   Han, Seung Hwan ^a   Oh, Pyung Chun ^a   Shin, Eak Kyun ^a   Quon, Michael J ^b  

^a Gachon University College of Medicine   (South Korea)

^b National Institutes of Health   (United States)

Author keywords

Atherosclerosis; Combination therapy; Endothelial dysfunction; Insulin resistance; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FLUINDOSTATIN; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; PLACEBO; QUINAPRIL; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PREFERENCE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; RISK REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; DRUG THERAPY, COMBINATION; ENDOTHELIUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 77950021829     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.007     Document Type: Review

References (106)

1. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657.
2. Kim J., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
3. Kim J.A., Koh K.K., Quon M.J. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol 2005, 25:889-891.
4. Koh K.K., Han S.H., Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005, 46:1978-1985.
5. Han S.H., Quon M.J., Kim J., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49:531-538.
6. Koh K.K., Quon M.J. Targeting converging therapeutic pathways to overcome hypertension. Int J Cardiol 2009, 132:297-299.
7. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
8. HOPE/HOPE-TOO Study Investigators Long-term effects of ramipril on cardiovascular events and on diabetes results of the HOPE Study Extension. Circulation 2005, 112:1339-1346.
9. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
10. Koh K.K., Ahn J.Y., Han S.H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003, 42:905-910.
11. Koh K.K., Quon M.J., Han S.H., et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006, 108:96-100.
12. Ciulla M.M., Paliotti R., Esposito A., et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004, 110:552-557.
13. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517.
14. Schiffrin E.L., Park J.B., Intengan H.D., Touyz R.M. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000, 101:1653-1659.
15. Yasunari K., Maeda K., Watanabe T., et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004, 43:2116-2123.
16. Cutler J.A., Davis B.R. Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation 2008, 117:2691-2704.
17. Messerli F.H., Bangalore S., Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008, 117:2706-2715.
18. Gurwitz J.H., Bohn R.L., Glynn R.J., et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993, 118:273-278.
19. Yusuf S., Ostergren J.B., Gerstein H.C., et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005, 112:48-53.
20. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
21. DREAM Trial Investigators, Bosch J., Yusuf S., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562.
22. Eriksson J.W., Jansson P.A., Carlberg B., et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008, 52:1030-1037.
23. Sjöstrand M., Eriksson J.W. Neuroendocrine mechanisms in insulin resistance. Mol Cell Endocrinol 2009, 297:104-111.
24. Folli F., Kahn C.R., Hansen H., Bouchie J.L., Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100:2158-2169.
25. Sharma A.M., Janke J., Gorzelniak K., Engeli S., Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609-611.
26. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004, 109:2054-2057.
27. Hermann T.S., Li W., Dominguez H., et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:1001-1008.
28. Koh K.K., Quon M.J., Han S.H., et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2008, 10.1016/j.ijcard.2008.11.017.
29. Koh K.K., Park S.M., Quon M.J. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008, 117:3238-3249.
30. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
31. Azizi M., Menard J. Combined blockade of the rennin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004, 109:2492-2499.
32. Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004, 329:1248-1249.
33. Strauss M.H., Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006, 114:838-854.
34. Reudelhuber T.L. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005, 46:1261-1262.
35. Widdop R.E., Jones E.S., Hannan R.E., Gaspari T.A. Angiotensin AT2 receptors: cardiovascular hope or hype?. Br J Pharmacol 2003, 140:809-824.
36. Kim M.P., Zhou M., Wahl L.M. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005, 78:195-201.
37. Strauss M.H., Lonn E.M., Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur Heart J 2005, 26:2351-2353.
38. Verdecchia P., Angeli F., Gattobigio R., Reboldi G.P. Do angiotensin II receptor blockers increase the risk of myocardial infarction?. Eur Heart J 2005, 26:2381-2386.
39. McDonald M.A., Simpson S.H., Ezekowitz J.A., Gyenes G., Tsuyuki R.T. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005, 331:873.
40. ONTARGET Investigators, Yusuf S., Teo K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
41. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with Cardiovascular Disease (TRANSCEND) Investigators, Yusuf S., Teo K., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174-1183.
42. Han S.H., Quon M.J., Koh K.K. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007, 18:58-65.
43. Muniyappa R., Montagnani M., Koh K.K., Quon M.J. Cardiovascular actions of insulin. Endocr Rev 2007, 28:463-491.
44. Potenza M.A., Marasciulo F.L., Chieppa D.M., et al. Insulin resistance in spontaneously hypertensive rats (SHR) is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005, 289:H813-H822.
45. Potenza M.A., Marasciulo F.L., Tarquinio M., Quon M.J., Montagnani M. Treatment of spontaneously hypertensive rats (SHR) with rosiglitazone and/or enalapril simultaneously improves hypertension and insulin resistance by restoring balance between vasodilator and vasoconstrictor actions of insulin. Diabetes 2006, 55:3594-3603.
46. Wei Y., Whaley-Connell A.T., Chen K., et al. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007, 50:384-391.
47. Sydow K., Mondon C.E., Schrader J., Konishi H., Cooke J.P. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 2008, 28:692-697.
48. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanisms for insulin resistance. J Clin Invest 1990, 85:1844-1852.
49. Koh K.K., Son J.W., Ahn J.Y., et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004, 95:185-191.
50. Nickenig G., Sachinidis A., Michaelsen F., et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997, 95:473-478.
51. Nickenig G., Bäumer A.T., Temur Y., et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
52. Bokoch G.M., Prossnitz V. Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells. J Clin Invest 1992, 89:402-408.
53. Nakagami H., Jensen K.S., Liao J.K. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003, 35:398-403.
54. Hong H., Zeng J.S., Kreulen D.L., Kaufman D.I., Chen A.F. Atorvastatin protects against cerebral infarction via inhibiting NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol 2006, 291:H2210-H2215.
55. Dechend R., Fiebler A., Lindschau C., et al. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 2001, 14(6 Pt 2):55S-61S.
56. Hauck L., Harms C., Grothe D., et al. Critical role for FoxO3a-dependent regulation of p21CIP1/WAF1 in response to statin signaling in cardiac myocytes. Circ Res 2007, 100:50-60.
57. Rodriguez-Porcel M., Lerman L.O., Herrmann J., et al. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol 2003, 23:885-891.
58. Li Z., Iwai M., Wu L., et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004, 44:758-763.
59. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
60. Han S.H., Koh K.K., Quon M.J., Lee Y., Shin E.K. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 2007, 190:205-211.
61. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005, 45:1088-1093.
62. Koh K.K., Quon M.J., Han S.H., et al. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis 2007, 194:230-237.
63. Ceriello A., Assaloni R., Da Ros R., et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005, 111:2518-2524.
64. Radaelli A., Loardi C., Cazzaniga M., et al. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arterioscler Thromb Vasc Biol 2007, 27:2750-2755.
65. Han S.H., Quon M.J., Koh K.K. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor (PPAR)α Activators. Hypertension 2005, 46:1086-1092.
66. Koh K.K., Quon M.J., Rosenson R.S., Chung W.-J., Han S.H. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol 2008, 124:149-159.
67. Lee H.J., Choi S.S., Park M.K., et al. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002, 296:293-299.
68. Choi K.C., Ryu O.H., Lee K.W., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005, 336:747-753.
69. Ishibashi M., Egashira K., Hiasa K., et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002, 40:687-693.
70. Tao L., Liu H.R., Gao E., et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003, 108:2805-2811.
71. Hsueh W.A., Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004, 43:297-305.
72. Calnek D.S., Mazzella L., Roser S., Roman J., Hart C.M. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:52-57.
73. Hwang J., Kleinhenz D.J., Lassègue B., et al. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005, 288:C899-905.
74. Berger J.P., Akiyama T.E., Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005, 26:244-251.
75. Chetty V.T., Sharma A.M. Can PPARgamma agonists have a role in the management of obesity-related hypertension?. Vasc Pharmacol 2006, 45:46-53.
76. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008, 102:283-294.
77. Nicol C.J., Adachi M., Akiyama T.E., Gonzalez F.J. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005, 18:549-556.
78. Tham D.M., Martin-McNulty B., Wang Y.X., et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genom 2002, 11:21-30.
79. Diep Q.N., Amiri F., Touyz R.M., et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002, 40:866-871.
80. Sugawara A., Takeuchi K., Uruno A., et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001, 142:3125-3134.
81. Van Linthout S., Spillmann F., Lorenz M., et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 2009, 53:682-687.
82. Nakamura T., Yamamoto E., Kataoka K., et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008, 51:296-301.
83. Koh K.K., Han S.H., Quon M.J., Ahn J.Y., Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
84. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 2006, 29:195-201.
85. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
86. Rosenson R.S. Field of confusion: future prospects for fibrate therapy in cardiovascular disease. Curr Atheroscler Rep 2006, 8:219-222.
87. Szapary P.O., Bloedon L.T., Samaha F.F., et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:182-188.
88. Sarafidis P.A., Nilsson P.M. The effect of thiazolidinediones on blood pressure levels-a systematic review. Blood Press 2006, 15:135-150.
89. Qayyum R., Schulman P. Cardiovascular effects of the thiazolidinediones. Diabetes Metab Res Rev 2006, 22:88-97.
90. Qayyum R., Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006, 8:19-28.
91. Suwaidi J.A., Hamasaki S., Higano S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
92. Halcox J.P.J., Schenke W.H., Zalos G., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002, 106:653-658.
93. Juonala M., Viikari J.S., Laitinen T., et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns study. Circulation 2004, 110:2918-2929.
94. Halcox J.P., Donald A.E., Ellins E., et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation 2009, 119:1005-1012.
95. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295.
96. Koh K.K., Quon M.J., Waclawiw M.A. Are statins effective for simultaneously treating dyslipidemias and hypertension?. Atherosclerois 2008, 196:1-8.
97. Kushiro T., Mizuno K., Nakaya N., et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 2009, 53:135-141.
98. Williams B., Lacy P.S., Cruickshank J.K., et al. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation 2009, 119:53-61.
99. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
100. Demers C., McMurray J.J., Swedberg K., et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005, 294:1794-1798.
101. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
102. Chhatriwalla A.K., Nicholls S.J., Wang T.H., et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009, 53:1110-1115.
103. Koh K.K. Combination treatment to prevent atherosclerosis. Hypertension 2007, 50:e67.
104. Koh K.K., Quon M.J. Combination therapy for treatment or prevention of atherosclerosis. Hypertension 2008, 52:e18.
105. Koh K.K., Oh P.C., Quon M.J. Does reversal of oxidative stress and inflammation provide vascular protection?. Cardiovasc Res 2009, 81:649-659.
106. Koh K.K., Quon M.J. The importance of considering alternative or combination strategies for lowering LDL-C. Int J Cardiol 2009, 136:115-119.